Stephanie Joyce, PA, MSPAS, MS, RD - Planner
Jason Welch, MD - Planner
Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP - Peer Reviewer

In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC) to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

PRIME® designates the Enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME Credit. Approval is valid until 12/11/2025. PAs should only claim credit commensurate with the extent of their participation.

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.5 contact hour (which includes 0.35 hour of pharmacology).

This Knowledge-based activity has been approved for 0.5 contact hour (0 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-24-356-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion. Pharmacists with questions can contact NABP customer service ([email protected]).

PRIME® designates this activity for 0.5 contact hour.

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• Scott T. Tagawa, M.D., MS, FACP (Speaker, Contributing Author)

Consultant – Ambrx, Amgen, Bayer, Clarity, Convergent Therapeutics, Daiichi Sankyo, EMD Serono, General Electric, Gilead Sciences, Janssen, Lantheus, Merck, Myovant, Novartis, POINT Biopharma, Pfizer, Regeneron, Sanofi, Seagen, Telix, TransThera
Grants / Research Support – Ambrx, Amgen, Bayer, Clarity, Gilead Sciences, Janssen, Janux, Merck, Novartis, POINT Biopharma, Pfizer, Sanofi, Seagen, Telix
Other Financial or Material Support (royalties, patents, etc.) – Convergent Therapeutics, Gilead Sciences

The relationships reported above are related to the following therapeutic area: Oncology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP (Reviewer)
• Stephanie Joyce, PA, MSPAS, MS, RD (Planner)
• Jason Welch, MD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.

Obtaining CE Credit

1. Complete the activity in its entirety
2. Complete a post-activity evaluation
3. Download and/or print a certificate of completion and/or submit CE credits electronically

Device Requirements

• Computer, smartphone, tablet, or mobile device with audio capabilities and Internet connectivity

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

At PRIME, we are committed to ensuring that individuals with disabilities can access all of the content offered by PRIME through our website and other properties. If you are having trouble accessing primeinc.org, please email [email protected] for assistance. Please put "ADA Inquiry" in the subject line of your email.